Form 4: Prothena Director Richard Collier Receives Stock Options

Director Richard T. Collier was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.

Summary

• Director Richard T. Collier received a grant of 27,000 stock options on May 15, 2026.
• The options have an exercise price of $9.76 per share.
• The options are set to expire on May 15, 2036.
• Vesting is scheduled for the earlier of the first anniversary of the grant date or the 2027 annual general meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Vesting is subject to the director maintaining continuous service with the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for mid-cap biotechnology firms.
• The one-year cliff vesting schedule is typical for director equity awards in the industry.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of May 15, 2027, or the 2027 annual general meeting.

Key Dates

Keywords

Prothena, PRTA, Director Compensation, Stock Options, Insider Transaction, Equity Grant